

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l., (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 0775)

## **BUSINESS UPDATE**

### **AGREEMENT TO DISTRIBUTE BIOLIDICS' SEROLOGY TEST FOR COVID-19**

The board of directors of CK Life Sciences Int'l., (Holdings) Inc. (the “**Company**”) announces that CK Life Sciences Int'l., Inc. (a wholly-owned subsidiary of the Company) (“**CKLSII**”) has entered into a distribution agreement pursuant to which Biolidics Limited, a Singapore-based medical technology company (“**Biolidics**”), has appointed CKLSII as its distributor in Hong Kong for its ISO certified serology test for COVID-19 (the “**Test**”). The Test has received provisional authorisation from the Health Sciences Authority of Singapore to be used in Singapore for COVID-19 testing. The Company believes that the Test is a timely option to help expedite the testing of the increasing number of suspected COVID-19 cases in Hong Kong.

By Order of the Board  
**CK Life Sciences Int'l., (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 15 April 2020

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Colin Stevens Russel (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director) and Mr. Paul Joseph Tighe (Independent Non-executive Director).*